What it is
BPC-157 is a chain of fifteen amino acids (sequence GEPPPGKPADDAGLV). It corresponds to a partial sequence of a larger protein called Body Protection Compound, originally identified in human gastric juice. The material used clinically is made synthetically.
The mechanisms attributed to it come almost entirely from laboratory and rodent research. The most consistently reported is an effect on new blood vessel formation: in animal tissue, BPC-157 appears to act through the VEGFR2–Akt–eNOS signaling pathway, one of the routes the body uses to grow capillaries into healing tissue. Related work describes modulation of the nitric oxide system, increased growth hormone receptor expression in tendon fibroblasts, and reductions in several inflammatory cytokines.
Tendon, ligament, and cartilage heal slowly in part because they are poorly vascularized, so a molecule that plausibly improves local blood supply is a reasonable thing to study there. Whether it does so at a clinically meaningful level in a human being is a separate question, and it is not yet answered.
What the research shows
The evidence base is preclinical. That is the honest summary.
The most useful single reference is a 2025 systematic review in HSS Journal, the peer-reviewed journal of the Hospital for Special Surgery. Reviewers identified 36 studies of BPC-157 in musculoskeletal healing. Thirty-five were animal studies. One was human: 12 patients with chronic knee pain who received intra-articular injection, of whom 7 reported relief lasting more than six months — uncontrolled and unblinded. The reviewers graded the body of evidence as Level IV and Level V, the two lowest tiers, and noted the absence of human clinical safety data.
Two caveats matter. Most of the published literature originates from a single research group in Croatia, with limited independent replication. And as reported by STAT in February 2026, a human safety trial registered in 2015 was withdrawn before outside review and never published.
Absence of controlled human data is not demonstrated safety. When the FDA restricted BPC-157 from compounding in 2023, it cited potential immunogenicity from peptide aggregation and peptide-related impurities. Some investigators have also raised a theoretical concern that a compound promoting angiogenesis could in principle support blood supply to a tumor. That has not been shown in humans and is disputed by the original investigators, but it is unresolved and relevant to anyone with a cancer history.
BPC-157 has a coherent mechanistic rationale and a consistent preclinical signal. It does not have the human evidence that would let any physician tell you what it will do for you.
Who may be a candidate
- Adults with a persistent tendon, ligament, or soft-tissue complaint that has not responded to a well-executed course of conventional care
- Patients under evaluation for chronic gastrointestinal irritation, including irritation associated with long-term NSAID use, where much of the animal literature sits
- Post-injury or post-surgical patients whose recovery has plateaued and in whom a correctable structural cause has been excluded
- Patients comfortable making an informed decision about an investigational compound under genuine uncertainty and monitoring
It is generally not appropriate in active or recent malignancy, in pregnancy or breastfeeding, for drug-tested competitive athletes, or for anyone unwilling to commit to follow-up and lab monitoring.
What treatment looks like here
Nothing is prescribed at a first visit on the basis of a symptom alone.
Evaluation. Dr. St. Marie takes a full history, performs a physical examination including an osteopathic structural assessment, and reviews prior imaging.
Laboratory work. Baseline testing typically includes a complete blood count, a comprehensive metabolic panel covering liver and kidney function, and hs-CRP — extending, by presentation, to metabolic markers, vitamin D, iron studies, thyroid function, and sex hormones. Impaired healing is often downstream of poorly controlled glucose, iron deficiency, low vitamin D, untreated sleep apnea, or a hormone deficit.
Route. When used, BPC-157 is most often given by subcutaneous injection, and for a well-localized problem may be directed near the affected region. Oral preparations are sometimes discussed for gastrointestinal complaints, with the caveat that oral bioavailability for a peptide of this size is not established in humans.
Monitoring and sourcing. Follow-up is scheduled, not optional. Labs are repeated and progress tracked objectively — range of motion, strength, validated pain scores, return to specific activities — against a stopping point agreed on in advance. If those measures have not moved by then, the trial ends. Where a preparation comes from is also a clinical question: material sold online as a “research chemical” is not made or tested to pharmaceutical standards, and the U.S. Anti-Doping Agency has warned that vial contents are frequently not what the label states.
FDA & regulatory status
BPC-157 is not an FDA-approved drug. It is not approved for tendon injury, joint pain, gut health, or any other indication, in the United States or anywhere else. It is not a lawful dietary supplement ingredient, and it appears on the Department of Defense Prohibited Dietary Supplement Ingredients List under DoDI 6130.06.
Its compounding status has changed repeatedly:
- In 2023, the FDA placed BPC-157 in Category 2 of its 503A bulk drug substances review — substances that may present significant safety risks — citing potential immunogenicity from aggregation and peptide-related impurities.
- In April 2026, BPC-157 was removed from Category 2 along with eleven other peptides. Removal did not place it on the 503A Bulks List; it defaults back to unapproved-new-drug status, which regulatory attorneys have described as a gray area rather than a green light.
- On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 for inclusion on the 503A Bulks List, as nominated for ulcerative colitis.
- That vote is advisory only. The FDA is not bound by it, and notice-and-comment rulemaking would have to be completed first — a process that could extend into 2027 or beyond.
- Even if it is eventually added, inclusion on the 503A Bulks List is not FDA approval of the drug. It governs what a compounding pharmacy may use as a starting material; it is not a finding of efficacy.
- BPC-157 does not appear on the 503B Bulks List, so it is not available through outsourcing facilities.
- The World Anti-Doping Agency has prohibited BPC-157 since January 1, 2022 under class S0, non-approved substances, in and out of competition. No therapeutic use exemption is available.
Questions we get
Is BPC-157 legal for a physician to prescribe? It sits in an unsettled area. It is not FDA-approved, and after the April 2026 changes it is not on the 503A Bulks List either. A July 2026 advisory committee recommended adding it, but the FDA has not completed the rulemaking that would give that effect.
Will BPC-157 help my tendon injury? No one can honestly tell you that it will. The animal literature is consistent, but the single published human musculoskeletal study included 12 patients and had no control group. It is being studied for soft-tissue repair; it has not been shown in adequate human trials to produce that result.
What about BPC-157 capsules sold online? BPC-157 is not a lawful dietary supplement ingredient, so it is not lawfully sold as one. Beyond that, material sold for “research use only” is not made or tested to pharmaceutical standards, and independent testing has repeatedly found such products mislabeled or contaminated.
Is it safe? That claim cannot responsibly be made, because there is no controlled human safety data. Anything used here is prescribed by a physician after individual evaluation, with laboratory monitoring and scheduled reassessment, precisely because the profile is not fully characterized.
I compete in a drug-tested sport. Can I use this? No. BPC-157 is prohibited at all times under WADA class S0, and no therapeutic use exemption is available for a non-approved substance. It is also on the Department of Defense prohibited ingredient list, which matters for active-duty service members.
Related
- 8 — Muscle, Joint, Mobility & Pain, where most patients first raise it
- 4 — Gut Health, where the majority of the original animal literature sits
- 2 — Inflammation, Disease Risk & Prevention, since impaired healing and chronic inflammation usually travel together
- 1 — Comprehensive Health Assessment & Foundation, because the evaluation that determines candidacy often finds a more treatable explanation
Next step
If you are considering BPC-157, the useful first step is not a prescription — it is a comprehensive evaluation. Dr. St. Marie will review your history, examine you, order appropriate laboratory work, and tell you plainly what is driving your symptoms and whether an investigational peptide belongs in the plan at all.
Candidacy for BPC-157 is determined by Dr. St. Marie through comprehensive evaluation and lab work. It is not appropriate for everyone.
To schedule, call 407-506-4776 or book online. Osteopathic Health of Orlando, 4625 Halder Lane, Suite C, Orlando, FL 32814.